NURO Stock Overview
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.61|
|52 Week High||US$38.75|
|52 Week Low||US$2.70|
|1 Month Change||-11.95%|
|3 Month Change||-16.63%|
|1 Year Change||0.84%|
|3 Year Change||-15.83%|
|5 Year Change||-86.58%|
|Change since IPO||-100.00%|
Recent News & Updates
We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|NURO||US Medical Equipment||US Market|
Return vs Industry: NURO exceeded the US Medical Equipment industry which returned -23.6% over the past year.
Return vs Market: NURO exceeded the US Market which returned -18.4% over the past year.
|NURO Average Weekly Movement||25.5%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: NURO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 26% a week.
Volatility Over Time: NURO's weekly volatility has decreased from 39% to 26% over the past year, but is still higher than 75% of US stocks.
About the Company
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.
NeuroMetrix Fundamentals Summary
|NURO fundamental statistics|
Is NURO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NURO income statement (TTM)|
|Cost of Revenue||US$2.26m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.45|
|Net Profit Margin||-37.86%|
How did NURO perform over the long term?See historical performance and comparison
Is NURO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NURO?
Other financial metrics that can be useful for relative valuation.
|What is NURO's n/a Ratio?|
Price to Sales Ratio vs Peers
How does NURO's PS Ratio compare to its peers?
|NURO PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
EKSO Ekso Bionics Holdings
TNON Tenon Medical
VERO Venus Concept
Price-To-Sales vs Peers: NURO is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (32.9x).
Price to Earnings Ratio vs Industry
How does NURO's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: NURO is good value based on its Price-To-Sales Ratio (3x) compared to the US Medical Equipment industry average (3.9x)
Price to Sales Ratio vs Fair Ratio
What is NURO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NURO's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of NURO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NURO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NURO's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NURO's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is NeuroMetrix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroMetrix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine NeuroMetrix's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
How has NeuroMetrix performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NURO is currently unprofitable.
Growing Profit Margin: NURO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NURO is unprofitable, but has reduced losses over the past 5 years at a rate of 57.8% per year.
Accelerating Growth: Unable to compare NURO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NURO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: NURO has a negative Return on Equity (-13.12%), as it is currently unprofitable.
Discover strong past performing companies
How is NeuroMetrix's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NURO's short term assets ($25.6M) exceed its short term liabilities ($1.7M).
Long Term Liabilities: NURO's short term assets ($25.6M) exceed its long term liabilities ($283.2K).
Debt to Equity History and Analysis
Debt Level: NURO is debt free.
Reducing Debt: NURO has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NURO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NURO has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 40.1% each year
Discover healthy companies
What is NeuroMetrix current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NURO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NURO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NURO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NURO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NURO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shai Gozani (56 yo)
Dr. Shai N. Gozani, M.D., Ph D., founded Neurometrix Inc. in 1996 and has been its President since 2002 and Chief Executive Officer since 1997 and its Secretary July 2008. He has been the Chairman of the B...
CEO Compensation Analysis
Compensation vs Market: Shai's total compensation ($USD557.66K) is about average for companies of similar size in the US market ($USD748.70K).
Compensation vs Earnings: Shai's compensation has increased whilst the company is unprofitable.
Experienced Management: NURO's management team is seasoned and experienced (8.9 years average tenure).
Experienced Board: NURO's board of directors are seasoned and experienced ( 11.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 84.2%.
NeuroMetrix, Inc.'s employee growth, exchange listings and data sources
- Name: NeuroMetrix, Inc.
- Ticker: NURO
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$25.292m
- Shares outstanding: 7.01m
- Website: https://www.neurometrix.com
Number of Employees
- NeuroMetrix, Inc.
- 4B Gill Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.